Bioethics in Practice: Considerations for Stopping a Clinical Trial Early

REFERENCES

1. ↵
   1. Wright JT Jr.,
   2. Williamson JD,
   3. Whelton PK

   SPRINT Research Group Wright JT Jr., Williamson JD, Whelton PK et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 11 26; 373 22: 2103- 2116. doi: 10.1056/NEJMoa1511939. pmid:26551272

   OpenUrlCrossRefPubMed
2. ↵
   1. Bassler D,
   2. Briel M,
   3. Montori VM,
   4. et al.

   Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010 3 24; 303 12: 1180- 1187. doi: 10.1001/jama.2010.310. pmid:20332404

   OpenUrlCrossRefPubMedWeb of Science
3. 1. Korn EL,
   2. Freidlin B,
   3. Mooney M.

   Bias and trials stopped early for benefit. JAMA. 2010 7 14; 304 2: 157- 158 ; author reply 158-159. doi: 10.1001/jama.2010.932. pmid:20628125

   OpenUrlCrossRefPubMed
4. 1. Ellenberg SS,
   2. DeMets DL,
   3. Fleming TR.

   Bias and trials stopped early for benefit. JAMA. 2010 Jul 14; 304 2: 158; author reply 158-159 doi: 10.1001/jama.2010.933. pmid:20628127

   OpenUrlCrossRefPubMed
5. 1. Goodman S,
   2. Berry D,
   3. Wittes J.

   Bias and trials stopped early for benefit. JAMA. 2010 Jul 14;304(2):157; author reply 158-159. doi: 10.1001/jama.2010.931.
6. ↵
   1. Korn EL,
   2. Freidlin B,
   3. Mooney M.

   Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. J Clin Oncol. 2009 4 1; 27 10: 1712- 1721. doi: 10.1200/JCO.2008.19.5339. pmid:19237631

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Dahlöf B,
   2. Sever PS,
   3. Poulter NR,
   4. et al.

   ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 9 10-16; 366 9489: 895- 906. pmid:16154016

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Zannad F,
   2. McMurray JJ,
   3. Krum H,
   4. et al.

   EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 1 6; 364 1: 11- 21. doi: 10.1056/NEJMoa1009492. pmid:21073363

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Cleophas TJ,
   2. Zwinderman AH.

   Statistics Applied to Clinical Studies. 5th ed. Dordrecht, Netherlands: Springer Science+Business Media BV; 2012.
10. ↵
    1. Pocock SJ.

    When to stop a clinical trial. BMJ. 1992 7 25; 305 6847: 235- 240. pmid:1392832

    OpenUrlFREE Full Text
11. ↵
    US Food and Drug Administration Institutional Review Boards. FDA: 21 CFR §56.111 . April 1, 2015 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.111. Accessed June 3, 2016.
12. ↵
    1. Chan S.

    6 hospitalized, one of them brain-dead, after drug trial in France. The New York Times . January 15, 2016 http://www.nytimes.com/2016/01/16/world/europe/french-drug-trial-hospitalization.html?_r=0. Accessed June 1, 2016.
13. ↵
    1. Fidler B.

    Verastem sinks as mesothelioma study halted for futility. Exome . September 28, 2015 http://www.xconomy.com/boston/2015/09/28/verastem-sinks-as-mesothelioma-study-halted-for-futility/#. Accessed June 1, 2016.
14. ↵
    1. Zannad F,
    2. Gattis Stough W,
    3. McMurray JJ,
    4. et al.

    When to stop a clinical trial early for benefit: lessons learned and future approaches. Circ Heart Fail. 2012 3 1; 5 2: 294- 302. doi: 10.1161/CIRCHEARTFAILURE.111.965707. pmid:22438522

    OpenUrlFREE Full Text
15. ↵
    1. Cannistra SA.

    The ethics of early stopping rules: who is protecting whom? J Clin Oncol. 2004 5 1; 22 9: 1542- 1545. pmid:15117977

    OpenUrlFREE Full Text